GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Asset Turnover

RemeGen Co (HKSE:09995) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. RemeGen Co's Revenue for the three months ended in Dec. 2023 was HK$0.0 Mil. RemeGen Co's Total Assets for the quarter that ended in Dec. 2023 was HK$6,046.7 Mil. Therefore, RemeGen Co's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. RemeGen Co's annualized ROE % for the quarter that ended in Dec. 2023 was 0.00%. It is also linked to ROA % through Du Pont Formula. RemeGen Co's annualized ROA % for the quarter that ended in Dec. 2023 was 0.00%.


RemeGen Co Asset Turnover Historical Data

The historical data trend for RemeGen Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Asset Turnover Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial - - 0.35 0.15 0.18

RemeGen Co Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 - 0.06 - 0.06

Competitive Comparison of RemeGen Co's Asset Turnover

For the Biotechnology subindustry, RemeGen Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RemeGen Co's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Asset Turnover distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Asset Turnover falls into.



RemeGen Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

RemeGen Co's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=1177.048/( (6723.953+6046.675)/ 2 )
=1177.048/6385.314
=0.18

RemeGen Co's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (0+6046.675)/ 1 )
=0/6046.675
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


RemeGen Co  (HKSE:09995) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

RemeGen Co's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=0/3759.612
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0 / 0)*(0 / 6046.675)*(6046.675/ 3759.612)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.6083
=ROA %*Equity Multiplier
=0.00 %*1.6083
=0.00 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

RemeGen Co's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=0/6046.675
=(Net Income / Revenue)*(Revenue / Total Assets)
=(0 / 0)*(0 / 6046.675)
=Net Margin %*Asset Turnover
= %*0
=0.00 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


RemeGen Co Asset Turnover Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co (HKSE:09995) Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).
Executives
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Rongchang Holding Group Ltd. 2103 Interests held jointly with another person
Yantai Rongda Venture Capital Center (limited Partnership) 2103 Interests held jointly with another person
Yang Minhua 2103 Interests held jointly with another person
Xiong Xiaobin 2103 Interests held jointly with another person
Wen Qingkai 2103 Interests held jointly with another person
Wei Jianliang 2103 Interests held jointly with another person
Wang Xudong 2103 Interests held jointly with another person
Wang Weidong 2201 Interest of corporation controlled by you
Wang Liqiang 2103 Interests held jointly with another person
I-nova Limited 2101 Beneficial owner
Lin Jian 2103 Interests held jointly with another person
Fang Jianmin 2103 Interests held jointly with another person
Deng Yong 2103 Interests held jointly with another person
Morgan Stanley 2201 Interest of corporation controlled by you

RemeGen Co (HKSE:09995) Headlines

No Headlines